| 1 |
NCT01483001 |
Completed |
Feasibility Study on Stem Cells Sensitivity Assay |
- Lung Cancer
- Colorectal Cancer
- Breast Cancer
|
- Drug: Cancer Stem Cells Sensitivity Assay
|
Interventional
|
Phase 2 |
- Associazione Oncologia Traslazionale
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
|
- Feasibility of the project
- Identification of LC, CRC and BC stem cells
- Sensitivity of LC, CRC and BC stem cells to anti-tumor agents in vitro
- Identification of effective drugs for a specific patient
|
23 |
All |
18 Years and older (Adult, Older Adult) |
NCT01483001 |
LIVONCO 2011/001
2011-003421-10 |
STELLA |
November 2011 |
September 2012 |
December 2013 |
December 1, 2011 |
January 14, 2015 |
|
- Department of Medical Oncology
Livorno, Italy
|
|
| 2 |
NCT01641003 |
Unknown † |
Isolation and Characterization of Cancer Stem Cells Using iFP Technique |
- Malignant Neoplasm of Breast
- Glioma
- Pancreatic Cancer
|
|
Observational
|
|
- Rambam Health Care Campus
|
Other |
- Time Perspective: Prospective
|
- Cancer stem cells percentage
|
15 |
All |
18 Years and older (Adult, Older Adult) |
NCT01641003 |
cancer stem cells.ctil |
|
July 2012 |
June 2014 |
June 2015 |
July 16, 2012 |
July 16, 2012 |
|
- Rambam Health Care Campus
Haifa, Israel
|
|
| 3 |
NCT02115958 |
Completed |
The Immunotherapy of Nasopharyngeal Cancer Using Cancer Stem Cells Vaccine |
|
- Biological: cancer stem cell vaccine
|
Interventional
|
Phase 1
Phase 2 |
- Fuda Cancer Hospital, Guangzhou
- University of Michigan
- Fuda Cancer Hospital, Guangzhou
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- The primary study purpose to determine the safety of immunization with cancer stem cells vaccine by the number of participants with adverse events
- The secondary objectives are to evaluate vaccine immune responses to the immunizations by the data of body measurements
|
40 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT02115958 |
CLN-001
201401 |
|
March 2014 |
May 2015 |
May 2015 |
April 16, 2014 |
June 3, 2015 |
|
- Biological treatment center in Fuda cancer hospital
Guangzhou, Guangdong, China
|
|
| 4 |
NCT02074046 |
Completed |
Safety Study of Cancer Stem Cell Vaccine to Treat Pancreatic Cancer |
|
- Biological: cancer stem cell vaccine
|
Interventional
|
Phase 1
Phase 2 |
- Fuda Cancer Hospital, Guangzhou
- University of Michigan
- Fuda Cancer Hospital, Guangzhou
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- The primary study purpose to determine the safety of immunization with cancer stem cells vaccine by the number of participants with adverse events
- The secondary objectives are to evaluate vaccine immune responses to the immunizations by the data of body measurements
|
40 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT02074046 |
CLP-001
201401 |
|
February 2014 |
March 2015 |
March 2015 |
February 28, 2014 |
June 3, 2015 |
|
- Biological treatment center in Fuda cancer hospital
Guangzhou, Guangdong, China
|
|
| 5 |
NCT02084823 |
Completed |
Vaccine Therapy in Treating Lung Cancer Patients With Cancer Stem Cells |
|
- Biological: cancer stem cell vaccine
|
Interventional
|
Phase 1
Phase 2 |
- Fuda Cancer Hospital, Guangzhou
- University of Michigan
- Fuda Cancer Hospital, Guangzhou
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- The primary study purpose to determine the safety of immunization with cancer stem cells vaccine by the number of participants with adverse events
- The secondary objectives are to evaluate vaccine immune responses to the immunizations by the data of body measurements
|
40 |
All |
20 Years to 80 Years (Adult, Older Adult) |
NCT02084823 |
CLL-001
201401 |
|
March 2014 |
October 2014 |
December 2014 |
March 12, 2014 |
June 3, 2015 |
|
- Biological treatment center in Fuda cancer hospital
Guangzhou, Guangdong, China
|
|
| 6 |
NCT02089919 |
Completed |
Cancer Stem Cells Vaccine Therapy in Treating Hepatocellular Cancer Patients |
|
- Biological: cancer stem cell vaccine
|
Interventional
|
Phase 1
Phase 2 |
- Fuda Cancer Hospital, Guangzhou
- University of Michigan
- Fuda Cancer Hospital, Guangzhou
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- The number of participants with adverse events
- The secondary objectives are to evaluate vaccine immune responses to the immunizations by the data of body measurements
|
40 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT02089919 |
CLH-001
201401 |
|
February 2014 |
February 2015 |
February 2015 |
March 18, 2014 |
June 3, 2015 |
|
- Biological treatment center in Fuda cancer hospital
Guangzhou, Guangdong, China
|
|
| 7 |
NCT02176746 |
Completed |
A Phase I/II Study of Active Immunotherapy With Cancer Stem Cells Vaccine for Colorectal Cancer |
|
- Biological: cancer stem cell vaccine
|
Interventional
|
Phase 1
Phase 2 |
- Fuda Cancer Hospital, Guangzhou
- University of Michigan
- Fuda Cancer Hospital, Guangzhou
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- The number of participants with adverse events
- The secondary objectives are to evaluate vaccine immune responses to the immunizations by the data of body measurements
|
40 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT02176746 |
CLC-001 |
CSC |
June 2014 |
May 2015 |
May 2015 |
June 27, 2014 |
June 3, 2015 |
|
- Biological treatment center in Fuda cancer hospital
Guangzhou, Guangdong, China
|
|
| 8 |
NCT02530047 |
Active, not recruiting |
Mesenchymal Stem Cells (MSC) for Ovarian Cancer |
|
- Genetic: MSC-INFβ
- Behavioral: Questionnaires
|
Interventional
|
Phase 1 |
- M.D. Anderson Cancer Center
- M.D. Anderson Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD) of Mesenchymal Stem Cells-Interferon-β (MSC-IFNβ)
- Correlation Between the Number of MSC-IFNβ Infused and the Production of Interferon-β and the Number of MSC-IFNβ Detected at the Tumor Sites Via Tumor Biopsy Pre- and Post-Treatment
|
5 |
Female |
18 Years to 90 Years (Adult, Older Adult) |
NCT02530047 |
2013-0032
CA 136411
NCI-2015-01504 |
|
May 16, 2016 |
May 2019 |
May 2019 |
August 20, 2015 |
July 9, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
|
| 9 |
NCT01286883 |
Terminated |
Cancer Stem Cell Markers and Prognostic Markers in Circulating Tumor Cells |
|
|
Observational
|
|
- Milton S. Hershey Medical Center
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Primary endpoint: correlation of stem cell markers on CTCs with response to therapy
- Secondary Outcome: Correlation of stem cell markers in primary tumors with stem cell markers in CTCs
|
33 |
All |
18 Years and older (Adult, Older Adult) |
NCT01286883 |
PSHCI 10-066
PSHMC IRB No. 34902EP |
|
February 2011 |
February 2014 |
September 2014 |
January 31, 2011 |
August 20, 2018 |
|
- Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States
|
|
| 10 |
NCT01190345 |
Completed |
Anti Cancer Stem Cell Activity of Pre-operative Bevacizumab and Chemotherapy in Breast Cancer |
|
- Drug: bevacizumab
- Drug: no bevacizumab
|
Interventional
|
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Measure of the anti-cancer stem cell activity
- Evaluation of the safety of the treatment
- Evaluation of the disease-free survival, recurrence-free survival and overall survival
- Evaluation of the pathological complete response rate
|
75 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01190345 |
AVASTEM/IPC 2009-001 |
AVASTEM |
May 2010 |
July 24, 2012 |
October 6, 2017 |
August 27, 2010 |
August 13, 2018 |
|
- Jean-Marc EXTRA, MD
Marseille, France - Jean-Yves PIERGA
Paris, France - Hervé CURE
Reims, France
|
|
| 11 |
NCT01983709 |
Terminated |
Allogeneic Human Bone Marrow Derived Mesenchymal Stem Cells in Localized Prostate Cancer |
|
- Biological: Allogeneic Human Mesenchymal Stem Cells
|
Interventional
|
Phase 1 |
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Amount of systemically infused (MSC) DNA relative to recipient DNA at sites of prostate cancer in men with localized adenocarcinoma of the prostate that are scheduled to undergo a prostatectomy
- Feasibility of infusing MSCs into men with localized prostate cancer who plan to undergo a prostatectomy.
- Determine the proportion of MSC to recipient DNA in the peripheral blood
- (and 10 more...)
|
7 |
Male |
18 Years to 100 Years (Adult, Older Adult) |
NCT01983709 |
J1348
NA_00083720 |
MSC |
October 2013 |
June 2017 |
June 2017 |
November 14, 2013 |
July 16, 2018 |
|
- Johns Hopkins Hospital
Baltimore, Maryland, United States
|
|
| 12 |
NCT00429572 |
Completed
Has Results |
Mini-Allogeneic Peripheral Blood Progenitor Cell Transplantation For Recurrent or Metastatic Breast Cancer |
|
- Drug: Fludarabine
- Drug: Melphalan
- Procedure: Stem Cell Infusion
|
Interventional
|
Phase 2 |
- M.D. Anderson Cancer Center
- M.D. Anderson Cancer Center
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Tumor Response
- Overall Survival
- Time to Progressive Disease
- (and 2 more...)
|
19 |
All |
18 Years to 60 Years (Adult) |
NCT00429572 |
DM97-268 |
|
January 1998 |
May 2008 |
May 2008 |
January 31, 2007 |
August 7, 2012 |
July 13, 2011 |
- U.T.M.D. Anderson Cancer Center
Houston, Texas, United States
|
|
| 13 |
NCT02178670 |
Completed |
Safety and Effectivity Immunotherapy to Treat Ovarian Cancer With Cancer Stem Cells Vaccine |
|
|
Interventional
|
Phase 1
Phase 2 |
- Fuda Cancer Hospital, Guangzhou
- University of Michigan
- Fuda Cancer Hospital, Guangzhou
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- The primary study purpose to determine the safety of immunization with cancer stem cells vaccine by the number of participants with adverse events
- The secondary objectives are to evaluate vaccine immune responses to the immunizations by the data of body measurements
|
40 |
Female |
18 Years to 75 Years (Adult, Older Adult) |
NCT02178670 |
CLO-001
201401 |
|
June 2014 |
April 2015 |
April 2015 |
July 1, 2014 |
June 3, 2015 |
|
- Biological treatment center in Fuda cancer hospital
Guangzhou, Guangdong, China
|
|
| 14 |
NCT01075893 |
Completed |
Changes in Stem Cells of the Colon in Response to Increased Risk of Colorectal Cancer |
|
|
Observational
|
|
- Newcastle University
- Northumbria Healthcare NHS Foundation Trust
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Number of stem cells in the colonic crypt
- Stem cell position in colonic crypt
|
11 |
All |
18 Years to 85 Years (Adult, Older Adult) |
NCT01075893 |
McCallum-001 |
|
February 2010 |
October 2012 |
October 2012 |
February 25, 2010 |
October 31, 2017 |
|
- Wansbeck General Hospital
Ashington, Tyne & Wear, United Kingdom - North Tyneside Hospital
North Shields, Tyne & Wear, United Kingdom
|
|
| 15 |
NCT00405327 |
Completed |
A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation |
- Sarcoma
- Neuroblastoma
- Wilm's Tumor
|
- Biological: Tumor lysate-pulsed dendritic cell (DC) vaccine
- Other: Hematopoietic stem cell transplantation (HSCT)
|
Interventional
|
Phase 2 |
- University of Michigan Rogel Cancer Center
- University of Michigan Rogel Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To estimate the rate of immune response of this immunotherapy treatment
- To correlate and characterize the immune response to the clinical response.
- To define immunologic endpoints that can serve as surrogates of clinical response.
|
16 |
All |
up to 30 Years (Child, Adult) |
NCT00405327 |
UMCC 2005.050
GCRC ID # 2191
HUM00002650 |
|
June 2006 |
June 2009 |
June 2010 |
November 30, 2006 |
November 6, 2017 |
|
- University of Michigan, Department of Surgery, Pediatric Section
Ann Arbor, Michigan, United States
|
|
| 16 |
NCT00429507 |
Completed
Has Results |
Sm-EDTMP and Autologous Peripheral Blood Stem Cell Transplantation for Breast Cancer Patients With Bone Only Metastases |
- Breast Cancer
- Bone Metastases
|
- Drug: 153 Sm-EDTMP
- Behavioral: Questionnaire
- Procedure: Stem Cell Transplant
|
Interventional
|
Phase 2 |
- M.D. Anderson Cancer Center
- Cytogen Corporation
- M.D. Anderson Cancer Center
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
12 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00429507 |
2006-0349
NCI-2010-00573 |
|
March 2007 |
November 2014 |
November 2014 |
January 31, 2007 |
November 24, 2015 |
November 24, 2015 |
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
|
| 17 |
NCT01374841 |
Recruiting |
Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors |
|
- Drug: Cyclophosphamide
- Other: Hematopoietic Stem Cell Transplantation,
|
Interventional
|
Phase 2 |
- European Institute of Oncology
- European Institute of Oncology
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Donor engraftment
- Incidence and severity of graft versus host disease
- Non-relapse-related mortality
|
20 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01374841 |
IEO S513/110
2009-018083-94 |
|
August 2010 |
August 2019 |
December 2019 |
June 16, 2011 |
September 20, 2018 |
|
- European Institute of Oncology
Milan, Italy
|
|
| 18 |
NCT00610415 |
Completed |
Biopsy of Human Tumors for Cancer Stem Cell Characterization: a Feasibility Study |
- Head and Neck Cancer
- Head and Neck Cancers
|
|
Observational
|
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Quantification of the cancer stem cell population by flow cytometry
|
40 |
All |
18 Years and older (Adult, Older Adult) |
NCT00610415 |
ENT0023
98543
SU-12142007-934
10514 |
|
December 2007 |
October 2012 |
|
February 8, 2008 |
July 1, 2016 |
|
- Stanford University School of Medicine
Stanford, California, United States
|
|
| 19 |
NCT00003432 |
Terminated |
Immunotherapy in Treating Patients With Metastatic Breast Cancer |
|
- Biological: carcinoembryonic antigen RNA-pulsed DC cancer vaccine
|
Interventional
|
Phase 1
Phase 2 |
- Duke University
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Evaluate the ability of active immunotherapy with carcinoembryonic antigen (CEA) RNA pulsed dendritic cells to induce CEA specific T cells in patients with metastatic breast cancer in complete remission following peripheral blood stem cell transplant.
- Determine the clinical efficacy in terms of overall and recurrence free survival of immunotherapy with CEA RNA pulsed dendritic cells in this patients population.
|
4 |
All |
18 Years and older (Adult, Older Adult) |
NCT00003432 |
2030
IRB 2030
CDR0000066458 |
|
June 1998 |
November 2002 |
November 2002 |
April 25, 2003 |
November 6, 2013 |
|
- Duke Comprehensive Cancer Center
Durham, North Carolina, United States
|
|
| 20 |
NCT03407040 |
Enrolling by invitation |
Generation of Cancer Antigen-Specific T-cells From Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential FutureTherapy |
- Gastrointestinal Cancers
- Breast Cancer
- Pancreatic Cancer
- (and 2 more...)
|
|
Observational
|
|
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Production of cancer antigen-specific T cells
- Availability of stored specimens and/or data
|
79 |
All |
16 Years to 100 Years (Child, Adult, Older Adult) |
NCT03407040 |
180043
18-C-0043 |
|
January 30, 2018 |
December 31, 2028 |
December 31, 2030 |
January 23, 2018 |
December 18, 2018 |
|
- National Institutes of Health Clinical Center
Bethesda, Maryland, United States
|
|
| 21 |
NCT03632798 |
Recruiting |
Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer |
|
- Diagnostic Test: ChemoID assay
- Drug: Chemotherapy
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Diagnostic
|
- Progression free survival (PFS)
- Median Overall Survival (OS)
- Objective Tumor Response
- HRQOL
|
300 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03632798 |
CG02EOC |
ACSCO |
August 1, 2018 |
July 30, 2021 |
January 31, 2022 |
August 15, 2018 |
January 8, 2019 |
|
- Univeristy of Mississippi Medical Center
Jackson, Mississippi, United States - Charleston Area Medical Center
Charleston, West Virginia, United States - Edwards Comprehensive Cancer Center - Cabell Huntington Hospital
Huntington, West Virginia, United States
|
|
| 22 |
NCT02570100 |
Recruiting |
Research and Analysis of the Mechanisms Involved in the Emergence of Breast Cancer Stem Cells (RepriM) |
|
- Procedure: Biological collection
|
Interventional
|
Not Applicable |
- Centre Oscar Lambret
- Institut National de la Santé Et de la Recherche Médicale, France
- Institut pour la Recherche sur le Cancer de Lille
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Complete histopathological response
- Evaluation of the expression of genes involved in reprogramming by immunohistochemistry and Reverse Transcription Polymerase Chain Reaction (RT-PCR) according to the rate of CSCs before, during and after chemotherapy.
- Evaluation of relapse-free survival
- Quantification of the frequency of Cancer Stem Cells (CSCs) among the population of Circulating Tumor Cells (CTCs).
|
100 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02570100 |
RepriM-1407 |
|
April 2015 |
October 2017 |
September 2020 |
October 7, 2015 |
July 28, 2016 |
|
- Centre Oscar Lambret
Lille, France
|
|
| 23 |
NCT00281879 |
Terminated
Has Results |
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer |
- Chronic Myeloproliferative Disorders
- Leukemia
- Lymphoma
- (and 4 more...)
|
- Biological: anti-thymocyte globulin
- Biological: filgrastim
- Drug: busulfan
- (and 14 more...)
|
Interventional
|
Phase 2 |
- OHSU Knight Cancer Institute
- National Cancer Institute (NCI)
- OHSU Knight Cancer Institute
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Disease Free Survival (DFS).
|
200 |
All |
up to 60 Years (Child, Adult) |
NCT00281879 |
CDR0000452794
P30CA016058
OHSU-TPI-9695-L
OHSU-540 |
|
February 2006 |
February 2008 |
March 2008 |
January 25, 2006 |
September 27, 2017 |
June 19, 2012 |
- OHSU Knight Cancer Institute
Portland, Oregon, United States
|
|
| 24 |
NCT03626285 |
Recruiting |
Bone Marrow Transplantation Using CD34-Selected Stem Cells From Related or Unrelated Donors in Treating Participants With Cancer or Other Disorders |
- Benign Neoplasm
- Bone Marrow Transplantation Recipient
- Hematopoietic Cell Transplantation Recipient
- Malignant Neoplasm
|
- Procedure: Bone Marrow Transplantation
- Device: CliniMACS CD34 Reagent System
- Procedure: Peripheral Blood Stem Cell Transplantation
|
Interventional
|
Not Applicable |
- OHSU Knight Cancer Institute
- National Cancer Institute (NCI)
- OHSU Knight Cancer Institute
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Recipient demographics (age, gender, ethnicity)
- Donor demographics (age, gender, degree of human leukocyte antigen [HLA]-mismatch with recipient)
- Graft characteristics (total cell dose, number of leukocytes, number of CD34 positive cells pre and post-processing, number of CD3 positive [T-cells] pre and post processing, % viability)
- (and 6 more...)
|
20 |
All |
up to 70 Years (Child, Adult, Older Adult) |
NCT03626285 |
IRB00010804
NCI-2018-00556
P30CA069533 |
|
August 6, 2017 |
December 31, 2020 |
December 31, 2020 |
August 13, 2018 |
August 13, 2018 |
|
- OHSU Knight Cancer Institute
Portland, Oregon, United States
|
|
| 25 |
NCT01424865 |
Unknown † |
Cancer Stem Cell Biomarkers as a Predictor of Response to Trastuzumab in Samples From Patients With Breast Cancer Previously Treated in the NSABP-B-31 Trial |
|
- Genetic: fluorescence in situ hybridization
- Other: immunohistochemistry staining method
- Other: immunologic technique
- Other: laboratory biomarker analysis
|
Observational
|
|
- NSABP Foundation Inc
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Case Control
- Time Perspective: Retrospective
|
- ALDH1 expression (percentage of stem cells within the tumor) and association with outcomes regardless of HER2 staining
- HER2 expression in cells with stem cell-like properties as a determinant of aggressiveness and response to trastuzumab in the adjuvant setting
|
1874 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01424865 |
NSABP B-31 ICSCA
NSABP-B31-ICSC-A |
|
November 2011 |
December 2015 |
|
August 29, 2011 |
May 8, 2015 |
|
|
|
| 26 |
NCT00141765 |
Completed
Has Results |
Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers |
- Wilms Tumor
- Fibrosarcoma
- Carcinoma, Round Cell
- (and 2 more...)
|
- Procedure: Myeloablative Chemotherapy
- Procedure: Stem Cell Rescue
|
Interventional
|
Phase 2 |
- University of Michigan Rogel Cancer Center
- University of Michigan Rogel Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percent of Participants With Progression Free Survival at 1 Year
|
25 |
All |
up to 21 Years (Child, Adult) |
NCT00141765 |
UMCC 9626
IRB 1996-195 |
|
January 1997 |
December 2008 |
February 2010 |
September 1, 2005 |
June 20, 2014 |
June 20, 2014 |
- The University of Michigan
Ann Arbor, Michigan, United States
|
|
| 27 |
NCT00432094 |
Recruiting |
Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors |
- Childhood Germ Cell Tumor
- Ovarian Cancer
- Teratoma
|
- Drug: carboplatin
- Drug: etoposide
- Drug: ifosfamide
- (and 5 more...)
|
Interventional
|
Phase 2 |
- Masonic Cancer Center, University of Minnesota
- Masonic Cancer Center, University of Minnesota
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (OS)
- Disease-free survival (DFS)
- Engraftment of platelets
- (and 2 more...)
|
25 |
All |
10 Years to 69 Years (Child, Adult, Older Adult) |
NCT00432094 |
2006LS032
UMN-MT2005-21
UMN-0608M90586 |
|
December 19, 2006 |
January 2019 |
January 2019 |
February 7, 2007 |
September 26, 2018 |
|
- Masonic Cancer Center at University of Minnesota
Minneapolis, Minnesota, United States
|
|
| 28 |
NCT00002772 |
Terminated |
S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer |
|
- Biological: filgrastim
- Drug: carboplatin
- Drug: carmustine
- (and 9 more...)
|
Interventional
|
Phase 3 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
- Eastern Cooperative Oncology Group
- (and 2 more...)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
602 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00002772 |
CDR0000064747
S9623
U10CA032102 |
|
July 1996 |
February 2004 |
February 2004 |
April 22, 2004 |
January 24, 2013 |
|
- Memorial Sloan-Kettering Cancer Center
New York, New York, United States
|
|
| 29 |
NCT01231022 |
Completed |
Study the Role of Stem Cell in Curing Drug Induced Liver Injury in Metastatic Breast Cancer (MBC) |
- Breast Neoplasms
- Neoplasm Metastasis
|
|
Observational
|
|
- Beijing Cancer Hospital
- Beijing Cancer Hospital
|
Other |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- Protective effection of peripheral hematopoietic stem cell infusion for DILI
- SNPs genotyping associated with Drug Induced Liver Injury
- Change of cytokines
|
52 |
Female |
18 Years to 70 Years (Adult, Older Adult) |
NCT01231022 |
DILI |
MBC |
August 2010 |
June 2011 |
June 2013 |
November 1, 2010 |
July 29, 2015 |
|
- Beijing Cancer Hospital
Beijing, China
|
|
| 30 |
NCT00020722 |
Terminated
Has Results |
Chemotherapy Followed by Peripheral Stem Cell Transplantation Plus Biological Therapy in Treating Women With Stage IV Breast Cancer |
|
- Biological: therapeutic autologous lymphocytes
- Drug: Ifosfamide, carboplatin, and etoposide (ICE) regimen
- Drug: Cyclophosphamide, Thiotepa, Carboplatin (CTC) or STAMP V (CTC)
- (and 2 more...)
|
Interventional
|
Phase 2 |
- Barbara Ann Karmanos Cancer Institute
- National Cancer Institute (NCI)
- Barbara Ann Karmanos Cancer Institute
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease-free Survival
- Overall Survival
|
7 |
Female |
18 Years to 120 Years (Adult, Older Adult) |
NCT00020722 |
CDR0000068707
P30CA022453
WSU-2007-033
RWMC-0634246 |
|
August 2007 |
March 2013 |
March 2013 |
January 27, 2003 |
February 17, 2016 |
March 30, 2015 |
- Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States
|
|
| 31 |
NCT01799694 |
Completed |
Stem Cells Treatment for the Local Urinary Incontinence After a Radical Prostate Cancer Surgery (HULPURO) |
|
- Drug: Inject of Autologous Adipose-derived stem cells
|
Interventional
|
Phase 2 |
- Instituto de Investigación Hospital Universitario La Paz
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Evaluate the feasibility and security of the autologous e-ASC for the urinary incontinence after a radical prostate cancer surgery
- Quality of life assessment using the SF-12 Questionnaire
- Adverse events
|
10 |
Male |
18 Years and older (Adult, Older Adult) |
NCT01799694 |
FLPURO-2009-01
2009-016298-14 |
FLPURO |
July 2011 |
February 2013 |
February 2013 |
February 27, 2013 |
March 8, 2013 |
|
- Hospital Universitario La Paz
Madrid, Spain
|
|
| 32 |
NCT00458653 |
Active, not recruiting |
Vaccination With Dendritic Cell/Tumor Fusions With Autologous Stem Cell Transplants in Patients With Multiple Myeloma |
|
- Biological: Dendritic Cell Tumor Fusion
|
Interventional
|
Phase 1 |
- Beth Israel Deaconess Medical Center
- Massachusetts General Hospital
- Dana-Farber Cancer Institute
- (and 3 more...)
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To assess the toxicity associated with vaccination of multiple myeloma patients with dendritic cell/myeloma fusions and GM-CSF prior to stem cell mobilization and following high dose chemotherapy with stem cell rescue.
- To determine whether tumor specific cellular and humoral immunity can be induced by serial vaccination with DC/tumor cell fusions in conjunction with high dose chemotherapy with stem cell rescue
- To determine if vaccination with DC/tumor cell fusions results in clinical disease response in patients with evidence of residual disease post-transplant
- To determine the time to disease progression in this participant population.
|
45 |
All |
18 Years and older (Adult, Older Adult) |
NCT00458653 |
04-098 |
|
April 2005 |
April 2012 |
June 2019 |
April 11, 2007 |
July 24, 2018 |
|
- Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States - Dana-Farber Cancer Institute/Brigham & Women's Hospital
Boston, Massachusetts, United States - Massachusetts General Hospital
Boston, Massachusetts, United States - Rambam Medical Center
Haifa, Israel
|
|
| 33 |
NCT02063893 |
Completed |
Safety Study of Cancer Stem Cell Vaccinie to Treat Breast Cancer |
|
|
Observational
|
|
- Fuda Cancer Hospital, Guangzhou
- University of Michigan
- Fuda Cancer Hospital, Guangzhou
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- The primary study purpose to determine the safety of immunization with cancer stem cells vaccinie by the number of participants with adverse events
- The secondary objectives are to evaluate vaccinie immune responses to the immunizations by the data of body measurements
|
40 |
Female |
30 Years to 75 Years (Adult, Older Adult) |
NCT02063893 |
CLB-001
201401 |
CSC |
January 2014 |
January 2015 |
February 2015 |
February 17, 2014 |
June 3, 2015 |
|
- Biological treatment center in Fuda cancer hospital
Guangzhou, Guangdong, China
|
|
| 34 |
NCT01445132 |
Completed |
Adoptive Cell Therapy for B-Cell Cancers in Patients After Stem Cell Transplantation |
- Chronic Lymphocytic Leukemia
|
- Drug: Allogeneic Cell Therapy w/ Tumor-derived Lypho
|
Interventional
|
Phase 1 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Primary Purpose: Treatment
|
- To evaluate the feasibility of administering ex-vivo costimulated/expanded tumor-derived lymphocytes (TDL) in patients with persistent or recurrent B-cell lymphoid malignancies (BCL) following treatment with allogeneic hematopoietic stem cell tr...
- To determine the safety of administering TDL in patients with persistent/recurrent BCL following alloHSCT.
|
11 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT01445132 |
070064
07-C-0064 |
|
January 11, 2007 |
April 24, 2013 |
April 24, 2013 |
October 3, 2011 |
July 4, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 35 |
NCT02331134 |
Recruiting |
Tissue and Hematopoietic/Mesenchymal Stem Cell for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer |
- Malignant Melanoma
- Head and Neck Cancer
|
|
Interventional
|
Not Applicable |
- University of Colorado, Denver
- Karsh Family Research Fund
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Tissue and Hematopoietic Stem Cell Collection
- Identify pharmacodynamic markers
|
20 |
All |
18 Years and older (Adult, Older Adult) |
NCT02331134 |
14-0842.cc |
|
May 13, 2015 |
March 2020 |
March 2020 |
January 6, 2015 |
December 3, 2018 |
|
- University of Colorado Cancer Center
Aurora, Colorado, United States
|
|
| 36 |
NCT00179803 |
Unknown † |
Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors |
- Glioblastoma
- Astrocytoma
- Pineoblastoma
- (and 2 more...)
|
- Procedure: Stem Cell Transplant
|
Interventional
|
Phase 2
Phase 3 |
- Ann & Robert H Lurie Children's Hospital of Chicago
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To determine if the use of sequential myeloablative chemotherapy with peripheral blood stem cell rescue will increase the overall survival rate in patients with newly diagnosed high risk CNS tumors
- The overall survival and progression free survival in children with recurrent CNS malignancies after obtaining a state of minimum residual disease with submyeloablative chemotherapy, surgery, and/or radiation.
- To determine the progression free survival and overall survival using sequential myeloablative chemotherapy as compared to historical controls with single autologous stem cell rescue following myeloablative chemotherapy.
- (and 2 more...)
|
50 |
All |
18 Months to 25 Years (Child, Adult) |
NCT00179803 |
BMT 0398 |
|
March 1998 |
January 2008 |
|
September 16, 2005 |
March 14, 2011 |
|
- Children's Memorial Hospital
Chicago, Illinois, United States
|
|
| 37 |
NCT01326728 |
Terminated
Has Results |
Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation |
- Chronic Myelogenous Leukemia
- Acute Myelogenous Leukemia
- Acute Lymphoblastic Leukemia
- (and 2 more...)
|
- Biological: Allogeneic stem cell transplant
|
Observational
|
|
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Immune Suppression
- Time to Progression After Allotransplant
- Overall Survival
- (and 5 more...)
|
56 |
All |
18 Years to 99 Years (Adult, Older Adult) |
NCT01326728 |
110125
11-C-0125 |
|
March 30, 2011 |
June 28, 2017 |
July 14, 2017 |
March 31, 2011 |
June 5, 2018 |
June 5, 2018 |
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 38 |
NCT01678443 |
Active, not recruiting
Has Results |
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies |
- Adult Nasal Type Extranodal NK/T-cell Lymphoma
- Anaplastic Large Cell Lymphoma
- Angioimmunoblastic T-cell Lymphoma
- (and 30 more...)
|
- Biological: indium In 111 anti-CD45 monoclonal antibody BC8
- Radiation: yttrium Y 90 anti-CD45 monoclonal antibody BC8
- Procedure: peripheral blood stem cell transplantation
|
Interventional
|
Phase 1 |
- Fred Hutchinson Cancer Research Center
- National Cancer Institute (NCI)
- Fred Hutchinson Cancer Research Center
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants With Dose Limiting Toxicities (DLT) of Yttrium-90 Anti-CD45
- Overall Response Rate
- Overall Survival
- (and 2 more...)
|
2 |
All |
18 Years and older (Adult, Older Adult) |
NCT01678443 |
2361.00
NCI-2012-01505
P01CA044991
P30CA015704 |
|
September 1, 1999 |
April 11, 2011 |
July 24, 2019 |
September 5, 2012 |
November 20, 2018 |
November 9, 2017 |
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States
|
|
| 39 |
NCT00006032 |
Terminated |
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer |
|
- Drug: etoposide
- Drug: ifosfamide
- Drug: topotecan hydrochloride
- Procedure: peripheral blood stem cell transplantation
|
Interventional
|
Phase 2 |
- H. Lee Moffitt Cancer Center and Research Institute
- National Cancer Institute (NCI)
- H. Lee Moffitt Cancer Center and Research Institute
|
Other / NIH |
- Primary Purpose: Treatment
|
|
|
Female |
18 Years to 64 Years (Adult) |
NCT00006032 |
MCC-12220
MCC-IRB-5699
NCI-G00-1809 |
|
March 2000 |
April 2001 |
April 2001 |
April 2, 2004 |
December 11, 2012 |
|
- H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
|
|
| 40 |
NCT00966498 |
Terminated |
Peripheral Blood Stem Cell Transplant (PBSCT) in Children With High Risk or Recurrent Solid Tumors |
- High Risk Solid Tumors
- Recurrent Solid Tumors
|
- Procedure: Peripheral Blood Stem Cell Transplant
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To determine the feasibility and toxicity of tandem high dose chemotherapy and peripheral blood stem cells rescue in patients with high-risk or recurrent solid tumors.
|
3 |
All |
up to 35 Years (Child, Adult) |
NCT00966498 |
1023-2003
PBSCT for ST |
|
May 2003 |
July 2011 |
July 2011 |
August 27, 2009 |
December 11, 2013 |
|
- Children's Healthcare of Atlanta
Atlanta, Georgia, United States - Emory University
Atlanta, Georgia, United States
|
|
| 41 |
NCT00002836 |
Completed |
Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer |
|
- Biological: Filgrastim (G-CSF)
- Drug: Carmustine
- Drug: Cisplatin
- (and 4 more...)
|
Interventional
|
Phase 3 |
- M.D. Anderson Cancer Center
- National Cancer Institute (NCI)
- M.D. Anderson Cancer Center
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Compare Effectiveness of Chemotherapy + Filgrastim to Filgrastim Alone
|
184 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00002836 |
DM95-047
P30CA016672
MDA-DM-95047
NCI-G96-1014
CDR0000065048 |
|
September 26, 1995 |
March 9, 2006 |
March 9, 2006 |
November 24, 2003 |
November 6, 2018 |
|
- University of Texas - MD Anderson Cancer Center
Houston, Texas, United States
|
|
| 42 |
NCT00020410 |
Completed |
Radiolabeled Monoclonal Antibody Followed by Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Metastatic Breast Cancer |
|
- Biological: filgrastim
- Procedure: peripheral blood stem cell transplantation
- Radiation: yttrium Y 90 monoclonal antibody B3
|
Interventional
|
Phase 1 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Primary Purpose: Treatment
|
|
|
All |
18 Years and older (Adult, Older Adult) |
NCT00020410 |
CDR0000068405
NCI-00-C-0206
NCI-213 |
|
February 2001 |
|
|
January 27, 2003 |
April 30, 2015 |
|
- Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
Bethesda, Maryland, United States - Center for Cancer Research
Bethesda, Maryland, United States
|
|
| 43 |
NCT00423514 |
Active, not recruiting |
Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease |
- Graft Versus Host Disease
- Leukemia
- Myelodysplastic Syndromes
|
- Biological: filgrastim
- Drug: clofarabine
- Drug: melphalan
- (and 6 more...)
|
Interventional
|
Phase 1
Phase 2 |
- Memorial Sloan Kettering Cancer Center
- National Cancer Institute (NCI)
- Memorial Sloan Kettering Cancer Center
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Relapse of leukemia
- Overall and disease-free survival
- Early post-transplant regimen-related severe morbidity (grade III to IV nonhematologic toxicity) and mortality as measured by the NCI Cancer Therapy Evaluation Program CTCAE v 3.0
|
42 |
All |
up to 54 Years (Child, Adult) |
NCT00423514 |
06-125
MSKCC-06125 |
|
November 2006 |
November 2019 |
November 2019 |
January 18, 2007 |
May 7, 2018 |
|
- Memorial Sloan-Kettering Cancer Center
New York, New York, United States
|
|
| 44 |
NCT01921387 |
Active, not recruiting
Has Results |
Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies |
- Recurrent B-Cell Non-Hodgkin Lymphoma
- Recurrent Hodgkin Lymphoma
- Recurrent Mantle Cell Lymphoma
- (and 5 more...)
|
- Procedure: Autologous Hematopoietic Stem Cell Transplantation
- Drug: Carmustine
- Drug: Cytarabine
- (and 5 more...)
|
Interventional
|
Phase 1
Phase 2 |
- Fred Hutchinson Cancer Research Center
- National Cancer Institute (NCI)
- Fred Hutchinson Cancer Research Center
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum-tolerated Dose (MTD) of Yttrium-90-BC8-DOTA
- Progression-free Survival Following Autologous Stem Cell Transplant (ASCT)
- Estimated Dose to Tumor Sites Based on the Tumor to Normal Organ Ratios Derived From Dosimetry Estimates Coupled With the Absorbed Dose to Normal Organs Based on the Administered Activity of Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8
- The Lowest Antibody (Yttrium 90-BC8-DOTA) Dose (mg/kg) That is Consistent With a Favorable Biodistribution Rate >= 80% in Lymphoma Patients
|
20 |
All |
18 Years and older (Adult, Older Adult) |
NCT01921387 |
2728.00
NCI-2013-01378
P01CA044991
P30CA015704 |
|
October 9, 2013 |
July 26, 2017 |
July 26, 2021 |
August 13, 2013 |
September 3, 2018 |
September 3, 2018 |
- Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States
|
|
| 45 |
NCT00004177 |
Completed |
Radiolabeled Monoclonal Antibody Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory or Recurrent Ovarian Epithelial Cancer |
|
- Biological: filgrastim
- Procedure: peripheral blood stem cell transplantation
- Radiation: indium In 111 monoclonal antibody MN-14
- Radiation: yttrium Y 90 monoclonal antibody MN-14
|
Interventional
|
Phase 1
Phase 2 |
- Garden State Cancer Center at the Center for Molecular Medicine and Immunology
- National Cancer Institute (NCI)
- Garden State Cancer Center at the Center for Molecular Medicine and Immunology
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
15 |
Female |
18 Years to 80 Years (Adult, Older Adult) |
NCT00004177 |
CDR0000067299
R03CA077146
CMMI-C-039A-98
NCI-H99-0044
NCI-V99-1570 |
|
August 1999 |
May 2002 |
|
April 16, 2004 |
June 22, 2011 |
|
- Garden State Cancer Center
Belleville, New Jersey, United States - St. Joseph's Hospital and Medical Center
Paterson, New Jersey, United States - University of Pennsylvania Cancer Center
Philadelphia, Pennsylvania, United States
|
|
| 46 |
NCT02745756 |
Withdrawn |
A Combined Cell Therapy Approach to the Treatment of Neuroblastoma |
- Neuroblastoma
- Neoplasms, Nerve Tissue
|
- Procedure: Autologous Hematopoietic Progenitor Cell Transplant
- Biological: KLH and Tumor Lysate Pulsed DC Vaccine
|
Interventional
|
Phase 1 |
- H. Lee Moffitt Cancer Center and Research Institute
- Johns Hopkins All Children's Hospital
- H. Lee Moffitt Cancer Center and Research Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Occurrence of Sufficient Tumor Cell Lysate and Dendritic Cells
- Occurrence of Dendritic Cell Related Adverse Events
|
0 |
All |
up to 21 Years (Child, Adult) |
NCT02745756 |
MCC-17181 |
|
April 14, 2016 |
August 21, 2017 |
August 21, 2017 |
April 20, 2016 |
August 30, 2017 |
|
|
|
| 47 |
NCT00002942 |
Completed |
Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer |
|
- Procedure: autologous bone marrow transplantation
- Procedure: peripheral blood stem cell transplantation
|
Interventional
|
Phase 3 |
- Wake Forest University Health Sciences
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
136 |
All |
18 Years to 60 Years (Adult) |
NCT00002942 |
CDR0000065391
CCCWFU-95496
NCI-G97-1145 |
|
June 1996 |
January 2000 |
December 2003 |
September 3, 2004 |
August 10, 2018 |
|
- Comprehensive Cancer Center of Wake Forest University Baptist Medical Center
Winston-Salem, North Carolina, United States
|
|
| 48 |
NCT02183805 |
Recruiting |
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Metastatic Triple-negative Breast Cancer |
- Carcinoma Breast Stage IV
|
- Drug: Abraxane,Cyclophosphamide,Carboplatin
|
Interventional
|
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free Survival
- Overall Survival
|
30 |
Female |
18 Years to 65 Years (Adult, Older Adult) |
NCT02183805 |
SYSUCC-004 |
|
June 2014 |
December 2019 |
December 2019 |
July 8, 2014 |
March 1, 2017 |
|
- Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
|
|
| 49 |
NCT00003943 |
Completed |
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Cancer. |
- Carcinoma of Unknown Primary
- Lung Cancer
|
- Biological: filgrastim
- Drug: carboplatin
- Drug: cyclophosphamide
- (and 3 more...)
|
Interventional
|
Phase 2 |
- Fox Chase Cancer Center
- National Cancer Institute (NCI)
- Fox Chase Cancer Center
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determine the one year progression-free survival
- Overall survival; safety of regimen; CR rate; lab correlates; pharmacokinetics
|
3 |
All |
18 Years and older (Adult, Older Adult) |
NCT00003943 |
CDR0000067136
FCCC-98039
NCI-G99-1535 |
|
September 1998 |
November 2000 |
February 2003 |
May 3, 2004 |
April 17, 2013 |
|
- Johns Hopkins Oncology Center
Baltimore, Maryland, United States - Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
|
|
| 50 |
NCT00523809 |
Terminated
Has Results |
Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor |
- Breast Cancer
- Ovarian Cancer
|
- Drug: Bevacizumab
- Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
- Drug: Fludarabine
- (and 2 more...)
|
Interventional
|
Phase 2 |
- M.D. Anderson Cancer Center
- M.D. Anderson Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free Survival (PFS)
|
5 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00523809 |
2006-0873 |
|
August 2007 |
October 2011 |
October 2011 |
September 3, 2007 |
January 28, 2013 |
January 28, 2013 |
- U.T.M.D. Anderson Cancer Center
Houston, Texas, United States
|
|
| 51 |
NCT00003927 |
Active, not recruiting |
Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer |
|
- Biological: filgrastim
- Drug: amifostine trihydrate
- Drug: cyclophosphamide
- (and 3 more...)
|
Interventional
|
Phase 1 |
- City of Hope Medical Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Feasibility of high dose chemotherapy in advance breast cancer patients.
|
15 |
All |
18 Years to 59 Years (Adult) |
NCT00003927 |
99002
P30CA033572
CHNMC-IRB-99002
ALZA-CHNMC-IRB-99002
NCI-G99-1527
CDR0000067115 |
|
April 22, 1999 |
January 2019 |
January 2019 |
December 11, 2003 |
March 12, 2018 |
|
- Cancer Center and Beckman Research Institute, City of Hope
Duarte, California, United States
|
|
| 52 |
NCT00068523 |
Completed |
Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies |
- Chronic Myeloproliferative Disorders
- Leukemia
- Lymphoma
- (and 3 more...)
|
- Biological: anti-thymocyte globulin
- Drug: cyclophosphamide
- Drug: cyclosporine
- (and 5 more...)
|
Interventional
|
Not Applicable |
- Case Comprehensive Cancer Center
- National Cancer Institute (NCI)
- Case Comprehensive Cancer Center
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Study the effectiveness of combining ultraviolet-B light therapy with allogeneic stem cell transplantation in treating patients who have hematologic malignancies.
|
10 |
All |
18 Years and older (Adult, Older Adult) |
NCT00068523 |
ICC7Y02
P30CA043703
CWRU-ICC-7Y02 |
|
June 2003 |
March 2004 |
|
September 11, 2003 |
June 11, 2010 |
|
- Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States
|
|
| 53 |
NCT00002837 |
Completed |
High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer |
|
- Biological: Filgrastim (G-CSF)
- Drug: Cyclophosphamide
- Drug: Doxorubicin Hydrochloride
- (and 2 more...)
|
Interventional
|
Phase 1
Phase 2 |
- M.D. Anderson Cancer Center
- National Cancer Institute (NCI)
- Bristol-Myers Squibb
- M.D. Anderson Cancer Center
|
Other / NIH / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Doses (MTD) of 4 courses Doxorubicin, Paclitaxel, + Cyclophosphamide followed by PBSC and G-CSF Support
|
21 |
All |
15 Years to 60 Years (Child, Adult) |
NCT00002837 |
DM95-156
P30CA016672
MDA-DM-95156
NCI-V96-1017
CDR0000065052 |
|
September 1995 |
January 2002 |
January 2002 |
July 1, 2004 |
July 31, 2012 |
|
- University of Texas - MD Anderson Cancer Center
Houston, Texas, United States
|
|
| 54 |
NCT00510315 |
Active, not recruiting |
Abdominal Obesity and Cardiovascular Risk Factors in Women Who Survived Cancer or a Related Illness Following Total Body Irradiation and Stem Cell Transplant |
- Leukemia
- Hodgkin's Lymphoma
- Non-Hodgkin's Lymphoma
- Myelodysplastic Syndrome
|
- Other: Questionnaires, Laboratory tests, Abdominal MRI
|
Observational
|
|
- Memorial Sloan Kettering Cancer Center
- Queen's University, Kingston, Ontario
- Weill Medical College of Cornell University
- Memorial Sloan Kettering Cancer Center
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Explore whether visceral adipose tissue is significantly higher in women who were treated with total body irradiation (TBI) plus stem cell transplant in comparison with women who were not
- Determine the differences in processes of changes, decisional balance for physical activity, body image, mood, and quality of life between the groups
- Determine the correlation between the amount of visceral adipose tissue and fasting levels of triglycerides, LDL, HDL, insulin, glucose, and HOMA-IR in both groups.
- To begin to characterize the psychosocial risk factors of the TBI plus stem cell transplant group, in relation to the comparison group, in order to inform a future targeted intervention to reduce risk.
|
11 |
Female |
18 Years to 49 Years (Adult) |
NCT00510315 |
07-092 |
|
July 2007 |
January 2020 |
January 2020 |
August 2, 2007 |
December 4, 2018 |
|
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
|
|
| 55 |
NCT00003972 |
Completed |
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage II or Stage IIIA Breast Cancer |
|
- Biological: filgrastim
- Biological: sargramostim
- Drug: busulfan
- (and 8 more...)
|
Interventional
|
Phase 3 |
- Fred Hutchinson Cancer Research Center
- National Cancer Institute (NCI)
- Fred Hutchinson Cancer Research Center
|
Other / NIH |
- Allocation: Randomized
- Primary Purpose: Treatment
|
|
280 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00003972 |
1316.00
FHCRC-1316.00
PSOC-1604
NCI-G99-1552
CDR0000067175 |
|
July 1998 |
March 2003 |
March 2003 |
May 3, 2004 |
April 2, 2010 |
|
- Fred Hutchinson Cancer Research Center
Seattle, Washington, United States
|
|
| 56 |
NCT00605800 |
Withdrawn |
Bone Marrow Derived Adult Liver Stem Cell Recruitment After Major Liver Resections: Correlation With Liver Regeneration and Hepatic Function |
|
|
Observational
|
|
- Memorial Sloan Kettering Cancer Center
- National Cancer Institute (NCI)
- Memorial Sloan Kettering Cancer Center
|
Other / NIH |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- To determine qualitatively and quantitatively whether bone marrow derived liver associated stem cells are mobilized from the bone marrow in patients undergoing major liver resections (3 or more liver segments).
- To determine whether a difference exist in the baseline levels of bone marrow derived liver associated stem cells between normal healthy subjects/ volunteers and cancer patients prior to liver surgery.
|
0 |
All |
18 Years and older (Adult, Older Adult) |
NCT00605800 |
06-017 |
|
March 2006 |
March 2009 |
March 2009 |
January 31, 2008 |
March 19, 2009 |
|
|
|
| 57 |
NCT01171469 |
Completed |
Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor |
- Brain Tumor
- Glioblastoma
- Medulloblastoma
- (and 2 more...)
|
- Biological: Dendritic Cells
- Drug: Imiquimod
|
Interventional
|
Phase 1 |
- Masonic Cancer Center, University of Minnesota
- Masonic Cancer Center, University of Minnesota
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose
- Time to Tumor Progression
|
8 |
All |
Child, Adult, Older Adult |
NCT01171469 |
2008LS053
0809M48641 |
|
September 2010 |
May 2012 |
June 2012 |
July 28, 2010 |
December 2, 2017 |
|
- Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, United States
|
|
| 58 |
NCT00003877 |
Completed |
Peripheral Stem Cell Transplantation With or Without Stromagen Following Chemotherapy in Treating Women With Metastatic Breast Cancer |
|
- Biological: filgrastim
- Drug: carboplatin
- Drug: cyclophosphamide
- (and 4 more...)
|
Interventional
|
Phase 1
Phase 2 |
- Roswell Park Cancer Institute
- National Cancer Institute (NCI)
- Roswell Park Cancer Institute
|
Other / NIH |
- Allocation: Randomized
- Primary Purpose: Treatment
|
|
30 |
Female |
18 Years to 64 Years (Adult) |
NCT00003877 |
CDR0000067043
P30CA016056
RPCI-DS-9828
CWRU-OSIR-1198
OSIRIS-101
NCI-G99-1516 |
|
September 1998 |
February 2000 |
December 2000 |
July 16, 2004 |
March 7, 2011 |
|
- Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States - Roswell Park Cancer Institute
Buffalo, New York, United States - Ireland Cancer Center
Cleveland, Ohio, United States
|
|
| 59 |
NCT00002977 |
Completed |
Melphalan and Thiotepa Followed by Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer in Complete Remission |
|
- Biological: filgrastim
- Drug: melphalan
- Drug: thiotepa
- Procedure: peripheral blood stem cell transplantation
|
Interventional
|
Phase 1 |
- Fred Hutchinson Cancer Research Center
- National Cancer Institute (NCI)
- Fred Hutchinson Cancer Research Center
|
Other / NIH |
- Primary Purpose: Treatment
|
|
45 |
Female |
18 Years to 60 Years (Adult) |
NCT00002977 |
1181.00
NCI-G97-1229
CDR0000065499 |
|
January 1997 |
November 2001 |
|
April 29, 2004 |
September 15, 2010 |
|
- Fred Hutchinson Cancer Research Center
Seattle, Washington, United States
|
|
| 60 |
NCT00074269 |
Terminated
Has Results |
Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Metastatic Breast Cancer |
|
- Biological: anti-thymocyte globulin
- Biological: filgrastim
- Biological: graft-versus-tumor induction therapy
- (and 6 more...)
|
Interventional
|
Phase 2 |
- University of California, San Diego
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Adverse Events
- Number of Participants With Long-term Engraftment of Allogeneic Stem Cells and Lymphocytes
- Number of Participants With Acute and Chronic Graft-versus-host Disease (GVHD)
- (and 4 more...)
|
5 |
Female |
18 Years to 60 Years (Adult) |
NCT00074269 |
UCSD-020815
CDR0000343758 |
|
July 2003 |
March 2008 |
March 2008 |
December 11, 2003 |
May 31, 2018 |
November 24, 2014 |
- Rebecca and John Moores UCSD Cancer Center
La Jolla, California, United States
|
|
| 61 |
NCT00003080 |
Completed |
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Persistent or Platinum Refractory Stage III or IV Ovarian Cancer |
|
- Drug: endocrine-modulating drug therapy
- Drug: melphalan
- Drug: mitoxantrone hydrochloride
- (and 3 more...)
|
Interventional
|
Phase 1 |
- Fred Hutchinson Cancer Research Center
- National Cancer Institute (NCI)
- Fred Hutchinson Cancer Research Center
|
Other / NIH |
- Primary Purpose: Treatment
|
|
|
Female |
18 Years to 60 Years (Adult) |
NCT00003080 |
1144.00
FHCRC-1144.00
NCI-G97-1329
CDR0000065775 |
|
September 1996 |
May 2001 |
May 2001 |
April 14, 2004 |
September 15, 2010 |
|
- Fred Hutchinson Cancer Research Center
Seattle, Washington, United States
|
|
| 62 |
NCT01341301 |
Completed
Has Results |
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies |
|
- Radiation: Total Body Irradiation
- Biological: Donor Lymphocyte Infusion (DLI)
- Drug: Cyclophosphamide
- (and 4 more...)
|
Interventional
|
Phase 2 |
- Sidney Kimmel Cancer Center at Thomas Jefferson University
- Thomas Jefferson University
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants That Experience One Year Relapse Free Survival After Undergoing Hematopoietic Stem Cell Transplant (HSCT)
- Pace of T-cell and B-cell Immune Recovery
- Regimen Related Toxicities Graded According to the National Cancer Institute (NCI) Common Toxicity Criteria, Version 3.0
- Incidence and Severity of GVHD, Graded According to Standard Criteria
|
25 |
All |
18 Years and older (Adult, Older Adult) |
NCT01341301 |
10D.06
2009-41 |
|
May 2010 |
November 4, 2013 |
August 7, 2014 |
April 25, 2011 |
April 25, 2018 |
March 16, 2018 |
- Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, United States
|
|
| 63 |
NCT00002784 |
Completed |
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer |
|
- Biological: filgrastim
- Drug: CMF regimen
- Drug: cyclophosphamide
- (and 9 more...)
|
Interventional
|
Phase 3 |
- International Breast Cancer Study Group
- International Breast Cancer Study Group
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease-free survival.
- Overall survival.
- Toxicity.
- Quality of life.
|
344 |
Female |
16 Years to 65 Years (Child, Adult, Older Adult) |
NCT00002784 |
CDR0000064834
IBCSG-15-95
EU-96021 |
15-95 |
June 1996 |
August 2011 |
December 2011 |
July 29, 2004 |
April 4, 2013 |
|
- Newcastle Mater Misericordiae Hospital
Newcastle, New South Wales, Australia - Royal Prince Alfred Hospital, Sydney
Sydney, New South Wales, Australia - Royal Adelaide Hospital
Adelaide, South Australia, Australia - (and 8 more...)
|
|
| 64 |
NCT00003136 |
Completed |
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer or Primary Peritoneal Cancer |
- Ovarian Cancer
- Primary Peritoneal Cavity Cancer
|
- Biological: filgrastim
- Drug: amifostine trihydrate
- Drug: carboplatin
- (and 2 more...)
|
Interventional
|
Phase 1
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
11 |
Female |
up to 65 Years (Child, Adult, Older Adult) |
NCT00003136 |
8433
UCCRC-8433
ALZA-97-005-ii
NCI-V97-1357 |
|
December 1996 |
December 2000 |
October 2001 |
August 24, 2004 |
February 11, 2013 |
|
- University of Chicago Cancer Research Center
Chicago, Illinois, United States
|
|
| 65 |
NCT00003297 |
Completed |
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Cancer |
|
- Drug: mitoxantrone hydrochloride
- Drug: thiotepa
- Drug: topotecan hydrochloride
- Procedure: peripheral blood stem cell transplantation
|
Interventional
|
Phase 1
Phase 2 |
- Georgetown University
- National Cancer Institute (NCI)
|
Other / NIH |
- Primary Purpose: Treatment
|
|
50 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00003297 |
CDR0000066235
P30CA051008
GUMC-97342
NCI-G98-1414 |
|
December 1997 |
January 2001 |
January 2001 |
July 8, 2004 |
March 24, 2011 |
|
- Vincent T. Lombardi Cancer Research Center, Georgetown University
Washington, District of Columbia, United States
|
|
| 66 |
NCT01907009 |
Unknown † |
A PHASEII STUDY EVALUATING INTRAVENOUS MELPHALAN WITH AUTOLOGOUS WHOLE BLOOD STEM CELL TRANSPLANTATION (PBSCT)OVER THREE CYCLES IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (MEL-CAP). |
- Castrate Resistant Prostate Cancer
|
- Drug: Melphalan
- Drug: Lenograstim
|
Interventional
|
Phase 2
Phase 3 |
- Barts & The London NHS Trust
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To determine the efficacy of intensified intravenous Melphalan with autologous whole blood stem cell transplantation in patients with castration resistant prostate cancer using progression free survival.
- To determine weather early falls (two weeks)in circulating tumor cells (CTC)predict the progression free survival
- To assess the changes in prostate specific antigen pre and post treament
- (and 3 more...)
|
39 |
Male |
18 Years and older (Adult, Older Adult) |
NCT01907009 |
MEL-CAP |
MEL-CAP |
January 2013 |
January 2016 |
September 2017 |
July 24, 2013 |
September 9, 2015 |
|
- St Batholowmew's Hospital NHS
London, United Kingdom
|
|
| 67 |
NCT00003413 |
Completed |
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer |
|
- Biological: filgrastim
- Drug: carmustine
- Drug: cisplatin
- (and 4 more...)
|
Interventional
|
Phase 2 |
- University of Maryland
- University of Maryland Greenebaum Cancer Center
|
Other |
- Primary Purpose: Treatment
|
|
32 |
Female |
18 Years to 70 Years (Adult, Older Adult) |
NCT00003413 |
CDR0000066426
MSGCC-9749
NCI-V98-1452 |
|
September 1998 |
February 2001 |
February 2001 |
August 3, 2004 |
September 24, 2009 |
|
- Marlene & Stewart Greenebaum Cancer Center, University of Maryland
Baltimore, Maryland, United States
|
|
| 68 |
NCT01504152 |
Completed |
International Travel Patterns and Health Preparations of Hematopoietic Stem Cell Transplant Recipients at Memorial Sloan-Kettering Cancer Center |
- Hematopoietic Stem Cell Transplant
|
- Behavioral: questionnaire
|
Observational
|
|
- Memorial Sloan Kettering Cancer Center
- Weill Medical College of Cornell University
- Memorial Sloan Kettering Cancer Center
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- prevalence of international travel
- international travel was during a high-risk specific period
- patients that sought pre-travel health advice
- travelers that becomes ill and required medical attention
|
519 |
All |
18 Years and older (Adult, Older Adult) |
NCT01504152 |
11-176 |
|
December 2011 |
July 2013 |
July 2013 |
January 5, 2012 |
July 12, 2013 |
|
- Memorial Sloan-Kettering Cancer Center
New York, New York, United States
|
|
| 69 |
NCT00008203 |
Completed |
Comparison of Biological Therapies Following Combination Chemotherapy and Bone Marrow or Peripheral Stem Cell Transplantation in Women With Stage II or Stage III Breast Cancer |
|
- Biological: aldesleukin
- Biological: recombinant interferon gamma
- Drug: carboplatin
- (and 5 more...)
|
Interventional
|
Phase 3 |
- Herbert Irving Comprehensive Cancer Center
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Primary Purpose: Treatment
|
|
|
Female |
18 Years to 65 Years (Adult, Older Adult) |
NCT00008203 |
CDR0000068387
CPMC-IRB-7608
CPMC-CAMP-014
NCI-G00-1890 |
|
May 1996 |
December 2005 |
May 2008 |
June 5, 2003 |
February 4, 2013 |
|
- Herbert Irving Comprehensive Cancer Center
New York, New York, United States
|
|
| 70 |
NCT00020176 |
Completed |
Allogeneic Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer |
|
- Biological: filgrastim
- Biological: therapeutic allogeneic lymphocytes
- Drug: cyclophosphamide
- (and 3 more...)
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
|
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT00020176 |
CDR0000067899
NCI-00-C-0119
NCI-1027 |
|
June 2000 |
|
August 2007 |
January 27, 2003 |
June 20, 2013 |
|
- Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
Bethesda, Maryland, United States - NCI - Center for Cancer Research
Bethesda, Maryland, United States
|
|
| 71 |
NCT00005612 |
Terminated |
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer |
|
- Biological: filgrastim
- Drug: carboplatin
- Drug: cyclophosphamide
- (and 4 more...)
|
Interventional
|
Phase 1
Phase 2 |
- H. Lee Moffitt Cancer Center and Research Institute
- National Cancer Institute (NCI)
- H. Lee Moffitt Cancer Center and Research Institute
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival
|
3 |
Female |
18 Years to 65 Years (Adult, Older Adult) |
NCT00005612 |
MCC-12085
MCC-IRB-5418
NCI-G00-1745 |
ETC |
August 1999 |
February 2004 |
February 2004 |
May 3, 2004 |
September 26, 2012 |
|
- H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
|
|
| 72 |
NCT00005993 |
Terminated |
Biological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast Cancer |
|
- Drug: aldesleukin
- Drug: filgrastim
- Drug: recombinant human stem cell factor
- Procedure: peripheral blood stem cell transplantation
|
Interventional
|
Phase 1 |
- Masonic Cancer Center, University of Minnesota
- National Cancer Institute (NCI)
- Masonic Cancer Center, University of Minnesota
|
Other / NIH |
- Primary Purpose: Treatment
|
|
|
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00005993 |
1999LS022
MT1998-21
NCI-G00-1803 |
|
May 1999 |
July 2005 |
July 2005 |
June 21, 2004 |
November 29, 2017 |
|
|
|
| 73 |
NCT03023631 |
Recruiting |
Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant |
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient
- Hematopoietic and Lymphoid Cell Neoplasm
|
- Biological: Recombinant Human Papillomavirus Nonavalent Vaccine
|
Interventional
|
Phase 4 |
- M.D. Anderson Cancer Center
- National Cancer Institute (NCI)
- M.D. Anderson Cancer Center
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Antibody response defined as numerically elevated antibody titer of any type at 1 month post-dose 3 (month 7)
- Incidence of adverse events graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03
- Antibody persistence at 6 months post-dose 3
- (and 2 more...)
|
48 |
All |
18 Years and older (Adult, Older Adult) |
NCT03023631 |
2016-0714
NCI-2018-02606
P30CA016672 |
|
April 23, 2017 |
April 30, 2019 |
April 30, 2019 |
January 18, 2017 |
November 21, 2018 |
|
- M D Anderson Cancer Center
Houston, Texas, United States
|
|
| 74 |
NCT00003392 |
Completed |
High-Dose Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer |
|
- Biological: filgrastim
- Drug: carboplatin
- Drug: cyclophosphamide
- (and 4 more...)
|
Interventional
|
Phase 2 |
- UNC Lineberger Comprehensive Cancer Center
- National Cancer Institute (NCI)
- UNC Lineberger Comprehensive Cancer Center
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
61 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00003392 |
LCCC 9727
UNC-LCCC-970135
NCI-G98-1446 |
|
September 1997 |
August 2002 |
January 2003 |
July 22, 2004 |
February 22, 2012 |
|
- Scripps Clinic
La Jolla, California, United States - University of California San Diego
La Jolla, California, United States - Walter Reed Army Medical Center
Washington, District of Columbia, United States - (and 11 more...)
|
|
| 75 |
NCT03641378 |
Recruiting |
Inpatient Palliative Care for Patients Undergoing Hematopoietic Stem Cell Transplantation |
|
- Other: Palliative Care Intervention
- Other: Standard Transplant Care
|
Interventional
|
Not Applicable |
- Massachusetts General Hospital
- National Institutes of Health (NIH)
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Patient-reported quality of life (QOL): Functional Assessment of Cancer Therapy - Bone Marrow Transplant (FACT-BMT)
- Patients' quality of life (QOL) longitudinally: FACT-BMT
- Patients' symptom burden
- (and 7 more...)
|
720 |
All |
18 Years and older (Adult, Older Adult) |
NCT03641378 |
18-261
R01CA222014 |
|
September 30, 2018 |
July 1, 2022 |
July 1, 2023 |
August 22, 2018 |
December 3, 2018 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 76 |
NCT00004087 |
Completed |
Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Colorectal Cancer or Pancreatic Cancer |
- Colorectal Cancer
- Pancreatic Cancer
|
- Biological: filgrastim
- Procedure: autologous bone marrow transplantation
- Procedure: peripheral blood stem cell transplantation
- (and 2 more...)
|
Interventional
|
Phase 1
Phase 2 |
- Garden State Cancer Center at the Center for Molecular Medicine and Immunology
- National Cancer Institute (NCI)
- Garden State Cancer Center at the Center for Molecular Medicine and Immunology
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
15 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT00004087 |
CDR0000067300
P01CA054425
CMMI-C-033-98
NCI-H99-0042
NCI-V99-1571 |
|
March 1997 |
May 2001 |
|
April 16, 2004 |
June 22, 2011 |
|
- Garden State Cancer Center
Belleville, New Jersey, United States - St. Joseph's Hospital and Medical Center
Paterson, New Jersey, United States - University of Pennsylvania Cancer Center
Philadelphia, Pennsylvania, United States
|
|
| 77 |
NCT00051311 |
Completed |
Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers |
|
- Procedure: Stem cell transplantation
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Primary Purpose: Treatment
|
|
62 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT00051311 |
030077
03-C-0077 |
|
January 3, 2003 |
September 25, 2014 |
September 25, 2014 |
January 8, 2003 |
November 22, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 78 |
NCT00923052 |
Terminated |
The Natural History of Solid Organ Cancer Stem Cells (SOCSC) |
- Hepatic Cancer
- Pancreatic Ductal Cancer
- Colorectal Cancer
- (and 2 more...)
|
|
Observational
|
|
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- To study and characterize both quantitatively and qualitatively SOCSC from various primary and metastatic solid organ cancers from time of surgery or other cancer directed therapy to time of recurrence or progression using an exhaustive list of ...
- To determine whether SOCSC are present in the blood and/or bone marrow, and study their quantitative and/or qualitative changes over the course of the disease, from time of initial presentation to time of recurrence and/or metastasis.To sp...
|
190 |
All |
16 Years to 100 Years (Child, Adult, Older Adult) |
NCT00923052 |
090079
09-C-0079 |
|
February 9, 2009 |
|
May 7, 2015 |
June 18, 2009 |
January 18, 2019 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 79 |
NCT00112593 |
Completed
Has Results |
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer |
- Accelerated Phase Chronic Myelogenous Leukemia
- Acute Undifferentiated Leukemia
- Adult Acute Lymphoblastic Leukemia in Remission
- (and 176 more...)
|
- Drug: fludarabine phosphate
- Radiation: total-body irradiation
- Procedure: peripheral blood stem cell transplantation
- (and 3 more...)
|
Interventional
|
Not Applicable |
- Fred Hutchinson Cancer Research Center
- National Cancer Institute (NCI)
- Fred Hutchinson Cancer Research Center
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Death From Regimen Toxicity or Opportunistic Infection
- Death From GVHD
- Successful Induction of Mixed Hematopoietic Chimerism as Assessed by the Percentage of Peripheral Blood T Cells That Are of Donor Origin
- (and 3 more...)
|
5 |
All |
up to 75 Years (Child, Adult, Older Adult) |
NCT00112593 |
1410.00
NCI-2010-00802
P30CA015704
P01CA018029 |
|
November 1999 |
November 2014 |
|
June 3, 2005 |
May 24, 2017 |
May 24, 2017 |
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States
|
|
| 80 |
NCT01139164 |
Terminated
Has Results |
Allogeneic Hematopoietic Stem Cell Transplantation With Reduced Intensity Pre-transplant Conditioning for the Treatment of High-risk Hematological Malignancies (V3) |
- Hematological Malignancies
|
- Drug: Regimen A
- Drug: Regimen B
- Drug: Regimen C
|
Interventional
|
Phase 2 |
- Medical University of South Carolina
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To Determine the Treatment-related Mortality Rate of Allogeneic Stem Cell Transplants Using Reduced-intensity Conditioning Regimens Within 1st 100-days.
- To Determine the Engraftment Rate of Allogeneic Stem Cell Transplants
- Morbidity of Allogeneic Stem Cell Transplants
|
78 |
All |
1 Year to 75 Years (Child, Adult, Older Adult) |
NCT01139164 |
101370
HR#19490 |
|
June 2010 |
September 2014 |
December 2015 |
June 8, 2010 |
July 11, 2018 |
March 10, 2016 |
- Medical University of South Carolina
Charleston, South Carolina, United States
|
|
| 81 |
NCT00003064 |
Unknown † |
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer |
- Fallopian Tube Cancer
- Ovarian Cancer
- Primary Peritoneal Cavity Cancer
|
- Biological: filgrastim
- Drug: carboplatin
- Drug: etoposide phosphate
- (and 4 more...)
|
Interventional
|
Phase 1
Phase 2 |
- Herbert Irving Comprehensive Cancer Center
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
Other / NIH |
- Primary Purpose: Treatment
|
|
30 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00003064 |
CDR0000065734
CPMC-IRB-7866
NCI-G97-1327 |
|
January 1997 |
|
|
April 18, 2003 |
January 6, 2014 |
|
- Herbert Irving Comprehensive Cancer Center
New York, New York, United States
|
|
| 82 |
NCT00003284 |
Unknown † |
High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Lung Cancer |
|
- Biological: filgrastim
- Drug: carboplatin
- Drug: etoposide
- (and 4 more...)
|
Interventional
|
Phase 2 |
- Herbert Irving Comprehensive Cancer Center
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
Other / NIH |
- Primary Purpose: Treatment
|
|
30 |
All |
Child, Adult, Older Adult |
NCT00003284 |
CDR0000066206
CPMC-IRB-7836
CU-CAMP-017
NCI-G98-1408 |
|
January 1998 |
|
|
August 13, 2004 |
January 6, 2014 |
|
- Herbert Irving Comprehensive Cancer Center
New York, New York, United States
|
|
| 83 |
NCT00004900 |
Completed |
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer |
|
- Biological: filgrastim
- Drug: anastrozole
- Drug: carboplatin
- (and 6 more...)
|
Interventional
|
Phase 2 |
- Hackensack Meridian Health
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
Other / NIH |
- Primary Purpose: Treatment
|
|
|
Female |
18 Years to 65 Years (Adult, Older Adult) |
NCT00004900 |
NU-HAC98B2
CDR0000067579
NCI-G00-1689 |
|
October 1999 |
|
August 2004 |
August 20, 2004 |
May 30, 2013 |
|
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Chicago, Illinois, United States
|
|
| 84 |
NCT00798811 |
Completed |
High-dose Chemotherapy With Autologous Stem Cell Rescue in Pediatric High-risk Brain Tumors |
|
- Procedure: high-dose chemotherapy and autologous stem cell rescue
|
Interventional
|
Phase 2 |
- Samsung Medical Center
- KSPNO stem cell transpantation committee
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- overall survival, event-free survival
- toxicity
|
100 |
All |
Child, Adult, Older Adult |
NCT00798811 |
2005-12-009 |
|
September 2008 |
October 2013 |
October 2015 |
November 26, 2008 |
October 19, 2016 |
|
- Samsung Medical Center
Seoul, Korea, Republic of
|
|
| 85 |
NCT00004906 |
Completed |
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer |
|
- Biological: filgrastim
- Drug: anastrozole
- Drug: carboplatin
- (and 8 more...)
|
Interventional
|
Phase 2 |
- Hackensack Meridian Health
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
Other / NIH |
- Primary Purpose: Treatment
|
|
|
Female |
18 Years to 65 Years (Adult, Older Adult) |
NCT00004906 |
NU-H97B1
CDR0000067586
NCI-G00-1682 |
|
October 1999 |
|
June 2001 |
August 23, 2004 |
May 30, 2013 |
|
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Chicago, Illinois, United States - Hackensack University Medical Center
Hackensack, New Jersey, United States - Ireland Cancer Center
Cleveland, Ohio, United States - University of Pennsylvania Cancer Center
Philadelphia, Pennsylvania, United States
|
|
| 86 |
NCT00027573 |
Completed |
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Unresectable Kidney Cancer |
|
- Biological: filgrastim
- Biological: therapeutic allogeneic lymphocytes
- Drug: cyclophosphamide
- (and 4 more...)
|
Interventional
|
Phase 2 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- Alliance for Clinical Trials in Oncology
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate
- Overall survival
- Disease-free survival
- (and 2 more...)
|
36 |
All |
up to 60 Years (Child, Adult) |
NCT00027573 |
CALGB-90003
U10CA031946
CDR0000069044 |
|
October 2001 |
June 2006 |
June 2006 |
January 27, 2003 |
July 14, 2016 |
|
- CCOP - Mayo Clinic Scottsdale Oncology Program
Scottsdale, Arizona, United States - Indiana University Cancer Center
Indianapolis, Indiana, United States - Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States - (and 3 more...)
|
|
| 87 |
NCT00003680 |
Unknown † |
Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer |
|
- Drug: CMF regimen
- Drug: cyclophosphamide
- Drug: fluorouracil
- (and 5 more...)
|
Interventional
|
Phase 3 |
- Scottish Cancer Therapy Network
- National Cancer Institute (NCI)
|
Other |
- Allocation: Randomized
- Primary Purpose: Treatment
|
|
300 |
Female |
18 Years to 60 Years (Adult) |
NCT00003680 |
CDR0000066782
SCTN-BR9810
EU-98054 |
|
November 1998 |
|
|
May 3, 2004 |
November 6, 2013 |
|
- C.R.C. Beatson Laboratories
Glasgow, Scotland, United Kingdom
|
|
| 88 |
NCT00429182 |
Completed
Has Results |
Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer |
- Breast Cancer
- Metastatic Breast Carcinoma
- Invasive Breast Carcinoma
|
- Drug: Carboplatin
- Drug: Cyclophosphamide
- Drug: Thiotepa
- Procedure: Stem Cell Transplant
|
Interventional
|
Phase 2 |
- M.D. Anderson Cancer Center
- M.D. Anderson Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Reduction in CTCs Following High-dose Chemotherapy With Purged Autologous Stem Cell Products
- Median Progression Free Survival (PFS)
|
32 |
All |
18 Years to 55 Years (Adult) |
NCT00429182 |
2006-0280 |
|
June 2007 |
February 2012 |
February 2012 |
January 31, 2007 |
April 10, 2013 |
April 10, 2013 |
- UT MD Anderson Cancer Center
Houston, Texas, United States
|
|
| 89 |
NCT01440127 |
Terminated |
Impact of Pretreatment With Metformin on Colorectal Cancer Stem Cells (CCSC) and Related Pharmacodynamic Markers |
|
|
Interventional
|
Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Expression of CD133 in tumors from patients treated or not treated with metformin
|
9 |
All |
18 Years to 79 Years (Adult, Older Adult) |
NCT01440127 |
Metformin CCSC |
|
August 2011 |
October 2012 |
October 2012 |
September 26, 2011 |
March 26, 2015 |
|
- Tufts Medical Center
Boston, Massachusetts, United States
|
|
| 90 |
NCT00393341 |
Completed |
Quantitation of Endothelial Progenitor Cells as Markers of Tumor Angiogenesis in Breast Cancer |
- Breast Cancer Stage IV
- Breast Cancer Stage I
- Breast Cancer Stage II
|
|
Observational
|
|
- Indiana University School of Medicine
- Breast Cancer Research Foundation
- Indiana University
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- To quantitate endothelial progenitor cells (EPCs) in early and advanced breast cancer patients. Different type of EPCs will be isolated from the blood and quantitated.
|
68 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00393341 |
0609-21
IUCRO-0168 |
EPC |
October 2006 |
May 2009 |
August 2009 |
October 27, 2006 |
August 31, 2015 |
|
- Indiana University
Indianapolis, Indiana, United States
|
|
| 91 |
NCT03032783 |
Recruiting |
A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity |
- Hematopoietic and Lymphoid Cell Neoplasm
|
- Radiation: Total-Body Irradiation
- Procedure: Donor Lymphocyte Infusion
- Drug: Cyclophosphamide
- (and 3 more...)
|
Interventional
|
Phase 2 |
- Sidney Kimmel Cancer Center at Thomas Jefferson University
- Thomas Jefferson University
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Survival (OS)
- Incidence of graft failure
- Incidence of non-relapse mortality
|
45 |
All |
18 Years and older (Adult, Older Adult) |
NCT03032783 |
16D.606 |
|
January 31, 2017 |
July 24, 2020 |
July 24, 2020 |
January 26, 2017 |
February 20, 2018 |
|
- Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, United States
|
|
| 92 |
NCT00262886 |
Completed |
Donor Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Relapsed or Refractory Metastatic Kidney Cancer |
|
- Biological: anti-thymocyte globulin
- Biological: graft-versus-tumor induction therapy
- Biological: therapeutic allogeneic lymphocytes
- (and 6 more...)
|
Interventional
|
Phase 2 |
|
Other |
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response rate based on tumor measurements at 1 year
- Toxicity as measured by NCI CTC at days 0, 7, 14, 21 and 28 after transplantation and monthly for 11 months
- Overall and disease-free survival at day 100 and 1 year after transplantation
|
35 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT00262886 |
CDR0000449939
URCC-U1801
URCC-RSRB-09084 |
|
August 2001 |
July 2007 |
|
December 7, 2005 |
June 6, 2013 |
|
- James P. Wilmot Cancer Center at University of Rochester Medical Center
Rochester, New York, United States
|
|
| 93 |
NCT00245037 |
Completed
Has Results |
Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer |
- Chronic Myeloproliferative Disorders
- Leukemia
- Lymphoma
- (and 4 more...)
|
- Biological: therapeutic allogeneic lymphocytes
- Drug: busulfan
- Drug: cyclosporine
- (and 7 more...)
|
Interventional
|
Phase 1
Phase 2 |
- OHSU Knight Cancer Institute
- National Cancer Institute (NCI)
- OHSU Knight Cancer Institute
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Regimen-Related Toxicities
- Non-relapse Mortality
- Overall Survival
- (and 4 more...)
|
147 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT00245037 |
IRB00000210
P30CA016058
OHSU-HEM-05011-L
OHSU-210 |
Bu Flu TBI |
June 2005 |
August 2015 |
August 2015 |
October 27, 2005 |
September 27, 2017 |
July 2, 2017 |
- Knight Cancer Institute at Oregon Health and Science University
Portland, Oregon, United States
|
|
| 94 |
NCT00997529 |
Completed |
Mini Allo Stem Cell Transplantation for the Treatment of Solid Tumors |
|
- Drug: nonmyeloablative stem cell transplant
|
Interventional
|
Not Applicable |
- Beth Israel Deaconess Medical Center
- Amgen
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To determine the percent 100-day survival of patients with metastatic solid tumors undergoing non-myeloablative allogeneic stem cell transplantation (SCT).
- To determine the incidence of treatment-related toxicity and acute and chronic graft versus host disease.
- To determine the overall survival of patients with metastatic solid tumors undergoing non-myeloablative allogeneic SCT.
- To evaluate the tumor response in patients with metastatic solid tumors undergoing non-myeloablative allogeneic SCT.
|
14 |
All |
18 Years to 60 Years (Adult) |
NCT00997529 |
E-00-0154-FB/2001-P-000092/8 |
MiniSolid |
November 2000 |
November 2007 |
June 2010 |
October 19, 2009 |
July 18, 2016 |
|
- Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
|
|
| 95 |
NCT00938626 |
Completed |
Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma |
- Multiple Myeloma and Plasma Cell Neoplasm
|
- Biological: anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells
- Procedure: autologous hematopoietic stem cell transplantation
- Procedure: peripheral blood stem cell transplantation
|
Interventional
|
Phase 1 |
- Barbara Ann Karmanos Cancer Institute
- National Cancer Institute (NCI)
- Barbara Ann Karmanos Cancer Institute
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Cell-based toxicities according to NCI CTCAE v3.0 criteria
- Ability to mobilize the number of stem cells required for autologous peripheral blood stem cell transplantation (PBSCT)
- Engraftment of neutrophils
- (and 2 more...)
|
12 |
All |
18 Years and older (Adult, Older Adult) |
NCT00938626 |
CDR0000646891
P30CA022453
WSU-2008-106 |
|
October 2009 |
October 2011 |
March 2013 |
July 14, 2009 |
September 23, 2013 |
|
- Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States
|
|
| 96 |
NCT03531736 |
Recruiting |
T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Myeloid Malignancies and Aplastic Anemia |
|
- Drug: Antithymocyte globulin (Rabbit)
- Drug: fludarabine
- Radiation: total body irradiation
- (and 3 more...)
|
Interventional
|
Phase 1 |
- Memorial Sloan Kettering Cancer Center
- Memorial Sloan Kettering Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Rate of donor Neutrophil Engraftment
|
15 |
All |
18 Years and older (Adult, Older Adult) |
NCT03531736 |
17-639 |
|
May 9, 2018 |
May 2020 |
May 2020 |
May 22, 2018 |
November 20, 2018 |
|
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
|
|
| 97 |
NCT00004174 |
Completed |
Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer |
|
- Biological: filgrastim
- Drug: cyclophosphamide
- Drug: paclitaxel
- (and 3 more...)
|
Interventional
|
Phase 1 |
- Northwestern University
- National Cancer Institute (NCI)
|
Other / NIH |
- Primary Purpose: Treatment
|
|
30 |
All |
up to 60 Years (Child, Adult) |
NCT00004174 |
NU 96B1
NU-96B1
NCI-G99-1641 |
|
October 1999 |
May 2008 |
May 2008 |
April 28, 2004 |
July 10, 2013 |
|
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Chicago, Illinois, United States
|
|
| 98 |
NCT03712878 |
Recruiting |
2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies |
- Hematopoietic and Lymphoid Cell Neoplasm
|
- Radiation: Total-Body Irradiation
- Procedure: Donor Lymphocyte Infusion
- Drug: Cyclophosphamide
- (and 3 more...)
|
Interventional
|
Phase 2 |
- Sidney Kimmel Cancer Center at Thomas Jefferson University
- Thomas Jefferson University
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Donor T cell chimerism
- Relapse rate
- Incidence of grades II-IV graft versus host disease (GVHD)
- Rate of treatment-related mortality (TRM)
|
34 |
All |
18 Years and older (Adult, Older Adult) |
NCT03712878 |
18D.419 |
|
September 19, 2018 |
December 2020 |
December 2021 |
October 19, 2018 |
October 19, 2018 |
|
- Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, United States
|
|
| 99 |
NCT01728389 |
Unknown † |
Intrabone Transplantation of Allogenic Peripheral Blood Stem Cells in Patients With Myeloid and Lymphoid Malignancies. |
|
- Procedure: Intrabone transplantation
|
Interventional
|
Phase 1
Phase 2 |
- Maria Sklodowska-Curie Institute - Oncology Center
- Maria Sklodowska-Curie Institute - Oncology Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Neutrophil engraftment (ANC > 0,5 G/l)
- Lineage chimerism of peripheral blood T-cell lymphocytes
- Platelet engraftment (Plt > 20 G/l)
- Adverse reactions related with intrabone transplantation procedure
|
10 |
All |
18 Years to 55 Years (Adult) |
NCT01728389 |
IBT-COI-01 |
|
November 2012 |
December 2013 |
April 2014 |
November 19, 2012 |
July 24, 2013 |
|
- MSC Memorial CAncer Center and Institute of Oncology
Gliwice, Poland
|
|
| 100 |
NCT00004172 |
Completed |
Chemotherapy, Filgrastim, and Stem Cell Transplantation With Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer |
|
- Biological: filgrastim
- Drug: carboplatin
- Drug: cyclophosphamide
- (and 4 more...)
|
Interventional
|
Phase 2 |
- Northwestern University
- National Cancer Institute (NCI)
|
Other / NIH |
- Primary Purpose: Treatment
|
|
|
All |
up to 65 Years (Child, Adult, Older Adult) |
NCT00004172 |
NU 92B3T
NU-92B3T
NCI-G99-1640 |
|
October 1999 |
October 2003 |
October 2003 |
September 16, 2004 |
June 12, 2012 |
|
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Chicago, Illinois, United States
|
|
Create an RSS feed from your search for:
Download the search results for: